| scholarly article | Q13442814 |
| P2093 | author name string | Jacob M van Laar | |
| Steven O'Reilly | |||
| Thomas Hügle | |||
| P2860 | cites work | Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production | Q40849898 |
| Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma | Q41005869 | ||
| Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4 | Q41020866 | ||
| Interleukin-1 and B7/CD28 interaction regulate interleukin-6 production by human T cells. | Q41507647 | ||
| Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? | Q41614290 | ||
| An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors | Q41917400 | ||
| Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). | Q42101278 | ||
| C-reactive protein: a physiological activator of interleukin 6 receptor shedding. | Q42943901 | ||
| Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis | Q43877203 | ||
| IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent | Q44007756 | ||
| Cellular infiltrates in scleroderma skin | Q44017889 | ||
| Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis | Q44160763 | ||
| Dual roles of IL-4 in lung injury and fibrosis | Q44306912 | ||
| Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With Scleroderma | Q44338106 | ||
| Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent | Q44826352 | ||
| Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. | Q45937863 | ||
| Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. | Q51751505 | ||
| Disruption of the murine IL-4 gene blocks Th2 cytokine responses. | Q52516840 | ||
| GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. | Q54367655 | ||
| Increased expression of platelet-derived growth factor type b receptors in the skin of patients with systemic sclerosis | Q57351839 | ||
| Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule | Q24314704 | ||
| CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation | Q24672761 | ||
| Interleukin-13: central mediator of allergic asthma | Q28291712 | ||
| Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis | Q28510600 | ||
| Nonresolving inflammation | Q29616352 | ||
| Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma | Q31827052 | ||
| Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression | Q33471458 | ||
| Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome | Q33566618 | ||
| Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity | Q33567347 | ||
| Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. | Q33851819 | ||
| Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo | Q34146304 | ||
| Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis | Q34152922 | ||
| Lebrikizumab treatment in adults with asthma | Q34205683 | ||
| Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice | Q34276582 | ||
| Directing transition from innate to acquired immunity: defining a role for IL-6. | Q34449051 | ||
| Cyclophosphamide versus placebo in scleroderma lung disease. | Q34540647 | ||
| T cell anergy and costimulation | Q35096703 | ||
| T(H)1, T(H)2, and T(H)17 cells instruct monocytes to differentiate into specialized dendritic cell subsets | Q35230214 | ||
| Early T cell activation in the skin from patients with systemic sclerosis | Q35555856 | ||
| Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis | Q35566387 | ||
| Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages | Q35825861 | ||
| TNF downmodulates the function of human CD4+CD25hi T-regulatory cells | Q35849817 | ||
| Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells | Q36376543 | ||
| Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis | Q36599205 | ||
| Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis | Q36667816 | ||
| Efficient colonic mucosal wound repair requires Trem2 signaling | Q37068370 | ||
| IL-17-producing human peripheral regulatory T cells retain suppressive function | Q37176541 | ||
| Stem cell transplantation: a treatment option for severe systemic sclerosis? | Q37331071 | ||
| Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. | Q37408959 | ||
| Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling | Q40756159 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1540-1549 | |
| P577 | publication date | 2012-05-09 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | T cells in systemic sclerosis: a reappraisal | |
| P478 | volume | 51 |
| Q34148693 | A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells |
| Q58723092 | A Paradigmatic Interplay between Human Cytomegalovirus and Host Immune System: Possible Involvement of Viral Antigen-Driven CD8+ T Cell Responses in Systemic Sclerosis |
| Q92057941 | A follow-up study of occupational styrene exposure and risk of autoimmune rheumatic diseases |
| Q42133154 | A vitamin D analog inhibits Th2 cytokine- and TGFβ -induced periostin production in fibroblasts: a potential role for vitamin D in skin sclerosis |
| Q38829051 | Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes? |
| Q91782909 | Alternatively activated macrophages are associated with the α2AP production that occurs with the development of dermal fibrosis : The role of alternatively activated macrophages on the development of fibrosis |
| Q92639909 | Amelioration of bleomycin-induced pulmonary fibrosis via TGF-β-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells |
| Q54189017 | Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. |
| Q53512767 | Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. |
| Q41223874 | Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease. |
| Q61444734 | Attenuation of murine sclerodermatous models by the selective S1P receptor modulator cenerimod |
| Q35536149 | CD4-Positive T Cells and M2 Macrophages Dominate the Peritoneal Infiltrate of Patients with Encapsulating Peritoneal Sclerosis. |
| Q28080323 | Cellular Therapies in Systemic Sclerosis: Recent Progress |
| Q38364957 | Current frontiers in systemic sclerosis pathogenesis. |
| Q49507866 | Current perspectives on the role of CD8+ T cells in systemic sclerosis |
| Q55049680 | Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate. |
| Q38364855 | Early systemic sclerosis-opportunities for treatment. |
| Q51672074 | Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. |
| Q91845024 | Emerging targets of disease-modifying therapy for systemic sclerosis |
| Q38542589 | Environmental risk factors of systemic sclerosis |
| Q40321155 | Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. |
| Q92153763 | Evaluating the Regulation of Cytokine Levels After siRNA Treatment in Antigen-Specific Target Cell Populations via Intracellular Staining |
| Q38426474 | Extracorporeal photopheresis for the treatment of autoimmune diseases |
| Q38511454 | Genetics of systemic sclerosis. |
| Q34544210 | Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis |
| Q47774368 | IL-17 and related cytokines involved in systemic sclerosis: Perspectives |
| Q35078513 | IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway |
| Q47245797 | Increased expression and modulated regulatory activity of co-inhibitory receptors PD-1, TIGIT and TIM-3 in lymphocytes of systemic sclerosis patients |
| Q92525250 | Induction of a Th17 Phenotype in Human Skin-A Mimic of Dermal Inflammatory Diseases |
| Q53474166 | Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). |
| Q37683419 | Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. |
| Q38288110 | Interleukin-6: a new therapeutic target in systemic sclerosis? |
| Q92887080 | Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis |
| Q28067380 | MicroRNAs in fibrosis: opportunities and challenges |
| Q61805319 | Paraneoplastic scleroderma in the setting of CD30 large cell transformation of mycosis fungoides |
| Q38807643 | Photopheresis: Advances and Use in Systemic Sclerosis |
| Q94554113 | Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta |
| Q91721389 | Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases |
| Q36837811 | Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features |
| Q40292542 | Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment. |
| Q38173893 | Radiological thymus alterations in systemic sclerosis: our experience and a review of the literature |
| Q45782292 | Relationship between Rosai-Dorfman disease and IgG4-related disease: study of 32 cases |
| Q39129418 | Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis |
| Q38366114 | Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis |
| Q38132298 | Role of toll-like receptors in systemic sclerosis. |
| Q39029262 | Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-κB. |
| Q42369819 | Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study |
| Q37086513 | Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need |
| Q87345396 | Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis |
| Q36103285 | Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation |
| Q93160109 | Systemic Sclerosis is Linked to Psoriasis and May Impact on Patients' Survival: A Large Cohort Study |
| Q89217839 | Systemic sclerosis |
| Q38601631 | T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review |
| Q48298768 | Th1- and Th17-polarized immune infiltrates in eosinophilic fasciitis-A potential marker for histopathologic distinction from morphea. |
| Q36260811 | Th2-biased GATA-3 transgenic mice developed severe experimental peritoneal fibrosis compared with Th1-biased T-bet and Th17-biased RORγt transgenic mice |
| Q64095504 | The natural history of progressive fibrosing interstitial lung diseases |
| Q89670685 | Toll-like receptors in mediating pathogenesis in systemic sclerosis |
| Q38198637 | Tracking and treating activated T cells. |
| Q37381549 | Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives |
| Q41519827 | Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients |
| Q54288740 | Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. |
| Q59329331 | Unraveling SSc Pathophysiology; The Myofibroblast |
Search more.